KIFBP and rheumatoid arthritis: Our hypothesis is that DACRAs, due to their high potency [15] and ability to reduce bone and cartilage turnover [17], in combination with an anti-inflammatory treatment can provide clinical benefits in RA by reducing the destructive inflammation and thereby allow the potential bone- and cartilage-protective effects of the KBP to manifest, resulting in an improved outcome.